Skip to search formSkip to main contentSkip to account menu

Mabthera

National Institutes of Health

Related topics

Related topics

2 relations
Rituxan

Broader (1)

rituximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Background:Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both… 
Review
2013
Review
2013
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance
The increasing importance of targeting drugs in the treatment of several tumor entities (breast, colon, lung, malignant melanoma… 
Highly Cited
2012
Highly Cited
2012
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study…
BACKGROUND To describe incidence, risk factors, and influence of treatment on occurrence of central nervous system (CNS) relapse… 
Highly Cited
2011
Highly Cited
2011
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
BACKGROUND The aim of this subgroup analysis of the Mabthera International Trial Group study was to evaluate the impact of… 
Highly Cited
2010
Highly Cited
2010
Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Review
2010
Review
2010
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Rituximab (MabThera, Rituxan) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of… 
Highly Cited
2009
Highly Cited
2009
Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
2006
2006
Primary non-Hodgkin’s lymphoma of the mandibular gingiva with maxillary gingival recurrence
Review
2003
Review
2003
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
Rheumatoid arthritis (RA) is a complex condition that is well characterised by chronic inflammation in the synovial membrane of… 
Highly Cited
2001
Highly Cited
2001
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)